Willis Towers Watson Public Limited Company (WLTW) At $151.60 Forms Bottom; Arrowhead Pharmaceuticals (ARWR) Shorts Increased By 27.23%

Willis Towers Watson Public Limited Company (NASDAQ:WLTW) Logo

Willis Towers Watson Public Limited Company (WLTW) formed multiple bottom with $147.05 target or 3.00% below today’s $151.60 share price. Willis Towers Watson Public Limited Company (WLTW) has $19.99B valuation. The stock increased 0.17% or $0.26 during the last trading session, reaching $151.6. About 345,356 shares traded. Willis Towers Watson Public Limited Company (NASDAQ:WLTW) has risen 7.22% since June 30, 2017 and is uptrending. It has underperformed by 5.35% the S&P500. Some Historical WLTW News: 19/03/2018 – Willis Towers Watson expands strategic partnership to Plug and Play’s newest innovation platform; 09/05/2018 – Workplace Automation to Nearly Double in Indonesia in The Next 3 Years – Willis Towers Watson; 07/05/2018 – WILLIS TOWERS WATSON PLC WLTW.O FY2018 SHR VIEW $9.67 — THOMSON REUTERS l/B/E/S; 09/03/2018 – Willis Towers Watson launches the Global Ecosystem Resilience Facility; 07/05/2018 – Willis Towers Watson 1Q EPS $1.61; 12/04/2018 – Willis Towers Watson Expands Cybersecurity Services via Collaboration with IBM Security; 07/03/2018 – Willis Towers Watson Announces Analyst Day; 24/05/2018 – Eyeonid Group AB: Eyeonid Group AB (publ) and Willis Towers Watson has signed a Letter of Intent (LOI); 09/05/2018 – Less than half of U.S. workers willing to pay more for better health care benefits, Willis Towers Watson survey finds; 24/05/2018 – EYEONID GROUP AB EOID.NGM – SIGNS LOI WITH WILLIS TOWERS WATSON

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had an increase of 27.23% in short interest. ARWR’s SI was 5.78 million shares in June as released by FINRA. Its up 27.23% from 4.54M shares previously. With 1.95 million avg volume, 3 days are for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s short sellers to cover ARWR’s short positions. The SI to Arrowhead Pharmaceuticals Inc’s float is 8.45%. The stock increased 5.02% or $0.65 during the last trading session, reaching $13.6. About 1.60M shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 540.13% since June 30, 2017 and is uptrending. It has outperformed by 527.56% the S&P500. Some Historical ARWR News: 11/04/2018 – Arrowhead Pharma Presenting at Conference Tomorrow; 09/04/2018 – SUNROC: PURCHASE OF ARROWHEAD CONCRETE ASSETS OF WY CONCRETE; 15/05/2018 – Vivo Capital Buys New 2.2% Position in Arrowhead Pharma; 04/04/2018 – Interior-Parks: Special Tour of Arrowhead Pueblo Offered by Park; 27/03/2018 – Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B; 30/05/2018 – Jared® The Galleria Of Jewelry and Bremont Hosting a Special Event to Introduce the Popular Brand to Guests at Arrowhead Town Center Location; 21/05/2018 – Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis; 30/05/2018 – Jared® The Galleria Of Jewelry and Bremont Hosting a Special Event to Introduce the Popular Brand to Guests at Arrowhead Town; 11/04/2018 – Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™; 20/03/2018 – Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Analysts await Willis Towers Watson Public Limited Company (NASDAQ:WLTW) to report earnings on August, 2. They expect $1.69 EPS, up 16.55% or $0.24 from last year’s $1.45 per share. WLTW’s profit will be $222.81M for 22.43 P/E if the $1.69 EPS becomes a reality. After $2.71 actual EPS reported by Willis Towers Watson Public Limited Company for the previous quarter, Wall Street now forecasts -37.64% negative EPS growth.

Among 5 analysts covering Arrowhead Research (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Arrowhead Research has $1300 highest and $3 lowest target. $7.60’s average target is -44.12% below currents $13.6 stock price. Arrowhead Research had 12 analyst reports since January 4, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 18 by Cantor Fitzgerald. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, February 12. Cantor Fitzgerald has “Neutral” rating and $5 target. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Cantor Fitzgerald on Wednesday, May 30. The rating was maintained by B. Riley & Co with “Neutral” on Monday, February 12. FBR Capital maintained the stock with “Hold” rating in Monday, March 12 report. FBR Capital maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, February 12. FBR Capital has “Hold” rating and $4.0 target. Cantor Fitzgerald upgraded the shares of ARWR in report on Wednesday, May 9 to “Overweight” rating. The firm has “Hold” rating given on Tuesday, March 27 by FBR Capital.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Nasdaq.com which released: “The 3 Best Biotech Stocks of 2018 So Far” on June 28, 2018, also Fool.com with their article: “Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today” published on June 18, 2018, Schaeffersresearch.com published: “3 Drug Stocks Trading Near the Top of Nasdaq” on June 18, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Globenewswire.com and their article: “Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, US Silica, Catalent …” published on June 26, 2018 as well as Fool.com‘s news article titled: “3 Soaring Biotech Stocks. Can They Keep Climbing?” with publication date: June 21, 2018.

Willis Towers Watson Public Limited Company (NASDAQ:WLTW) Ratings Chart